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Abstract
Background: As weight gain is one of the most frequently cited reasons for not using and for
discontinuing hormonal contraceptives, in an open-label, single-arm, multicentre clinical study we
evaluated the effect of the ethinylestradiol/norelgestromin contraceptive patch (EVRA, Janssen-
Cilag International, Belgium) on body composition using bioelectrical impedance analysis (BIA).
Methods: Body weight and impedance vector components (resistance (R) and reactance (Xc), at
50 kHz frequency, Akern-RJL Systems analyzer) were recorded before entry, after 1, 3 and 6
months in 182 Italian healthy women aged 29 yr (18 to 45), and with BMI 21.8 kg/m2 (16 to 31).
Total body water (TBW) was estimated with a BIA regression equation. Vector BIA was performed
with the RXc mean graph method and the Hotelling's T2 test for paired and unpaired data.
Results: After 6 months body weight increased by 0.64 kg (1.1%) and TBW increased by 0.51 L
(1.7%). The pattern of impedance vector displacement indicated a small increase in soft tissue
hydration (interstitial gel fluid). Body composition changes did not significantly differ among groups
of previous contraceptive methods. Arterial blood pressure did not significantly change over time.
Conclusion: After 6 months of treatment with the ethinylestradiol/norelgestromin contraceptive
patch we found a minimal, clinically not relevant, increase in body weight less than 1 kg that could
be attributed to an adaptive interstitial gel hydration. This fluctuation is physiological as confirmed
by the lack of any effect on blood pressure. This could be useful in increasing women's choice,
acceptability and compliance of the ethinylestradiol/norelgestromin contraceptive patch.
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The efficacy and safety of the ethinylestradiol/nore-
lgestromin contraceptive patch compared to monophasic
and triphasic oral contraceptives have been demonstrated
in controlled, open-label pivotal studies, assessing 3,319
subjects for a total of 22,160 cycles [1].
A large open-label, single-arm, multicentre clinical study
(Phase IIIB/IV, NRGEEP-CON-402 "EVRA Contrast") has
been carried out in Europe to evaluate women's experi-
ence with the ethinylestradiol/norelgestromin contracep-
tive patch, specifically, user satisfaction and user
preference for the patch compared with their previous
method of contraception. The open study design with
broad selection criteria enabled the closest possible reflec-
tion of a routine clinical setting. Results will be published
in a different paper. A group of participant investigators
from Italy amended the study protocol including, as sec-
ondary objectives, an additional sub-study to assess body
composition with bioelectrical impedance analysis (BIA),
whose results will be presented in this paper.
BIA is a non invasive method specific for assessment of
soft tissue hydration based on the effect of the current
flow through intra- and extracellular ionic solutions. The
impedance vector Z is a combination of resistance (R) (i.e.
the opposition to flow of an alternating current through
intra and extracellular ionic solutions) and reactance (Xc)
(i.e. the capacitative component of tissue interfaces, and
cell membranes and organelles). The arc tangent of Xc/R
is called the phase angle. Measurements of Z vector are
used for assessment of total body water (TBW) either
through BIA regression equations or with Vector BIA [2-
5]. Contribution of bone to impedance is negligible, and
lean soft tissue contributes more than fat because adi-
pocyte droplets of triacylglycerols are non-conductors.
Although body impedance reflects tissue hydration, soft
tissue mass (lean and fat) can also be empirically derived
by correlation in healthy subjects because the compart-
ments of soft tissue are correlated with each other through
physiological constants. Physiological constants become
flawed in patients with fluid disorders, which accounts for
most conflicting results of literature [5]. An advantage of
the vector approach is the lack of reliance on regression
models to predict TBW and the inherent error associated
with the use of group models to predict individual TBW
[4,5].
The effect of hormonal contraceptives on body weight
gain is still debated. Weight gain is often considered one
of the most frequently cited side effects of using combined
contraceptives and many women and clinicians believe
that an association exists [6]. In a random survey con-
ducted in the UK, almost 75% of women reported that
weight gain was related to oral contraceptive use [7];
moreover, in one national study in the United States, 60%
of pill users who returned to their healthcare provider due
to side effects were concerned about weight gain [8]. In
Europe, about 30% of women surveyed from representa-
tive populations in Germany and France claimed to have
gained weight on their pills [9,10]. Concern about weight
gain limits the use of this highly effective method of con-
traception, especially in younger women, and can cause
early discontinuation or poor compliance among users.
Even the mere perception of weight gain, increased body
fat or fluid overload can lead to contraceptive discontinu-
ation. A national representative sample of American
women indicated that weight gain was the most common
single reason for discontinuing oral contraception: at 11%
this was a more frequent reason than nausea, headache
and menstrual abnormalities [11]. A survey of 6676
women from several European countries similarly found
that weight gain was among the most common com-
plaints and was associated with a 40% increased likeli-
hood of discontinuation [12]. However, a recent meta-
analysis did not find evidence supporting a causal associ-
ation between combination oral contraceptives or combi-
nation skin patch and weight gain. Authors concluded
that available evidence was insufficient to determine the
effect of combination contraceptives on weight, but no
large effect was evident [13]. Published studies with the
contraceptive patch (one pooled analysis of 3 clinical tri-
als, one placebo controlled trial and one comparative trial
versus a triphasic contraceptive pill) confirm that users of
the patch generally experience minimal changes in body
weight. For example, in the comparative trial of the patch
versus a pill containing levonorgestrel 50/75/125 μg +
ethinylestradiol 30/40/30 μg, the mean increase in body
weight was 0.41 kg in both treatment groups and the dis-
tribution of users who gained or lost weight or remained
within 5% of baseline weight during the trial was compa-
rable in the two groups [14]. However, as in real life
weight gain, perception of increased body fat or water
retention and fear of putting on weight remain big con-
cerns that can either deter the initiation of hormonal con-
traception or cause early discontinuation among users, we
think that the objective evaluation and monitoring of
body composition may contribute to improve the accept-
ability of estroprogestin methods to women. Therefore,
even if some studies did not show a significant increase in
body weight with the contraceptive patch, it is a challenge
for body composition analysis to determine if changes
occur in some compartments.
In this study we used BIA methods to evaluate body com-
position changes following the use of the ethinylestra-
diol/norelgestromin contraceptive patch for 6 months.Page 2 of 9
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Study design
This was a multicentre (24 Italian centres), open-label,
single-arm clinical study with treatment duration of 6
months, i.e. 6 treatment cycles of 4 weeks. Each site's Inde-
pendent Ethics Committees (IECs) approved the study
protocol and related amendments prior to the start of the
study, which was conducted, between June 2004 and
November 2005, in accordance with the Declaration of
Helsinki. Each ethinylestradiol/norelgestromin contra-
ceptive patch (EVRA: a three layers 20 cm2 contraceptive
patch which contains ethinylestradiol 0.6 mg and nore-
lgestromin 6.0 mg and delivers a daily dose of ethi-
nylestradiol 20 μg and norelgestromin 150 μg over the 7
days period – Janssen-Cilag International, Belgium) was
worn for one week and was replaced on the same day of
the week for three consecutive weeks. The fourth week was
"patch-free".
Four clinic visits were scheduled: a screening visit (T0),
followed by visits after one month (Cycle 1, T1), after 3
months (Cycle 3, T3) and after 6 months (Cycle 6, T6)
with the ethinylestradiol/norelgestromin contraceptive
patch.
At T0, the subject was asked about her method of contra-
ception used in the three months before entering the
study. Compliance was assessed at all visits by inspection
of returned study medication boxes and review of Diary
Cards in which the subject recorded the dates and sites of
patch applications and details in the case of any patch
detachments. A perfect compliance cycle was defined as
21 consecutive days of patch use with no patch worn
longer than 7 days and the patch-free interval minimally
1 and maximally 7 days. A subject compliant score (%)
was calculated as number perfect compliant cycles/
number ITT cycles per each woman.
Height was recorded at T0. Subjects were weighed (at the
nearest 100 g) lightly clothed (without shoes) at every
visit. Body mass index (BMI) was calculated as the body
weight (kg) divided by the square of the height (m).
Bioelectrical impedance analysis (BIA) was performed at
every visit. Standard, 50 kHz frequency, whole-body
tetrapolar measurements were obtained from a pair of
injector and detector electrodes on hand and foot [4,5].
Impedance vector components, Resistance (R) and Reac-
tance (Xc) were measured and recorded.
Inclusion criteria
18 to 45 yr old women, sexually active and at risk of preg-
nancy, having regular menstrual cycle occurring every 25
– 35 days (except for women using an implant), not preg-
nant, with a normal Pap smear within the previous 12
months, who agreed to use only the assigned study drug
as contraception during the study for up to 6 cycles. All
subjects signed the informed consent form.
Exclusion criteria
Known history or presence of disorders commonly
accepted as contraindications to hormonal contraceptives
including presence or history of venous or arterial throm-
bosis, migraine with focal aura, known or suspected carci-
noma of the breast or of the endometrium, liver disorders,
undiagnosed abnormal genital bleeding, alcohol or other
substance abuse, oily, irritated, or damaged skin at all
potential sites of application.
Study population
Two hundred and seven subjects were enrolled, under-
went the screening visit with planned investigations for
body composition analysis and used at least one contra-
ceptive patch (ITT population). Twenty five subjects were
excluded from statistical analysis: one obese subject with
a body weight of 110 kg and a BMI of 38 kg/m2, 9 subjects
with missing impedance measurements, and 15 subjects
with technical error in bioimpedance measurement (Xc/H
component > 60 Ohm/m with normal R/H component),
e.g. cream film on the skin of hand and foot. Statistical
analysis was performed on 182 subjects at T0. These sub-
jects were 29 yr old (18 to 45 yr), with BMI 21.8 kg/m2 (16
to 31 kg/m2), and height 163 cm (147 to 180 cm). At the
screening visit, subjects provided information about their
previous method of contraception (in the 3 months
before the study entry). None was declared by 92 subjects,
oral contraceptives by 40 subjects, barrier methods by 41
subjects, vaginal ring by 4 subjects, withdrawal method by
4 subjects, and natural family planning method by 1 sub-
jects.
During the study, compliance was remarkably good with
over 93% of the cycles with a perfect compliance and a
mean subject compliant score of 90%.
Twenty-one subjects failed to complete the study (3 at T1,
8 at T3, and 10 at T6), leaving for the analysis 179 subjects
at T1, 171 at T3 and 161 at T6. The reasons for study dis-
continuation were not related either to body weight gain
or to fluid retention (one pregnancy, failure to return n =
2, adverse reactions n = 8, subject's request unrelated to
study events n = 7, protocol violation n = 3). Adverse
events that led to withdrawal from the study were: head-
ache, spotting, breast pain, localised skin reactions (n = 4)
and libido reduction.
- Conventional BIA
TBW estimate (liters) using the impedance measurement
at the fixed frequency of 50 kHz was calculated with the
sex-specific, regression equation that have been recentlyPage 3 of 9
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has a standard error of the estimate of 2.6 L (bias 0.3 L)
and is recommended for healthy females with a normal
and fixed hydration of soft tissues (73%) [15]:
TBW (L) = 3.747 + 0.450 H2/R + 0.113 Weight (kg), where
H is the subject's height
- Vector BIA
Bioelectrical impedance vector analysis (BIVA or vector
BIA) was performed with the RXc graph method [2,3]. An
impedance measurement made at 50 kHz is considered a
bivariate, gaussian, random vector (Z) with two correlated
components, R and Xc normalized by the subject's height
(Z/H = (R/H, Xc/H), in Ohm/m). In contrast with regres-
sion equations of conventional BIA, direct measurements
are considered without assumptions. In an RXc mean
graph, mean impedance vectors are plotted as arrows with
their 95% confidence ellipses in the R-Xc plane. Overlap-
ping 95% confidence ellipses indicate no significant dif-
ference in vector position (not significant Hotelling's T2
test). Separate confidence ellipses indicate a significant (P
< 0.05) vector displacement (significant Hotelling's T2
test). Vector BIA only needs to take care of the measure-
ment error (2–3%) and of the biological variability of
subjects in any clinical condition. Body composition is
evaluated through patterns of vector position and dis-
placement [2-4,16]. In short, vector lengthening or short-
ening in the R-Xc plane, due to an increase or decrease in
both components R/H and Xc/H is associated with a
decrease or increase, respectively, in soft tissue hydration.
Recently, this basic Vector BIA pattern has been validated
in pregnancy using deuterium dilution as reference
method [4].
Statistical methods
The programs of the statistical package SPSS (ver. 15, Chi-
cago, IL) were used for standard calculations, including
one-way analysis of variance (ANOVA), Student's t test for
paired data, and linear correlation coefficient r. Vector
analysis was performed with BIVA software (Piccoli A, Pas-
tori G: BIVA software. Department of Medical and Surgical
Sciences, University of Padova, Padova, Italy, 2002. Avail-
able at E-mail: apiccoli@unipd.it) that allowed drawing
of 95% confidence ellipses and statistical testing with the
Hotelling's T2 test for paired and unpaired data [17] A test
P level of less than 0.05 was considered as statistically sig-
nificant.
Results
The aim of the study was to test whether a 6-month treat-
ment with the ethinylestradiol/norelgestromin contracep-
tive patch induced changes in body composition,
particularly in body fluid volume.
Average values of body weight, impedance vector compo-
nents, and estimates of TBW at T0, T1, T3, and T6 are
reported in Table 1. Body weight increased little but signif-
icantly over time: by 0.26 kg (0.4%) after 1 month, 0.42
kg (0.7%) after 3 months, and 0.64 kg (1.1%) after 6
months. TBW significantly increased by 0.49 L (1.6%)
after 3 months, and by 0.51 L (1.7%) after 6 months. After
3 months, the estimated TBW increase (0.49 L) was
greater than the body weight increase (0.42 kg), likely due
to the high standard error of the estimate of BIA predic-
tion equation [4,15]. The correlation between body
weight changes and TBW changes at T1, T3, and T6 versus
T0 was low and not significant (0.17 < r < 0.18).
Vector analysis of impedance documented a significant
vector displacement only after 6 months, when both R/H
Table 1: Distribution of body composition parameters over time
Body weight, kg R/H, Ohm/m Xc/H, Ohm/m TBW, L
Visit n M SD M SD M SD M SD
Screening visit, T0 182 58.1 8.1 373.6 53.6 39.8 6.5 30.4 3.6
After 1 month, T1 179 58.4 8.2 370.6 54.5 39.9 5.8 30.7 3.9
After 3 months, T3 171 58.4 8.1 369.1 58.0 39.3 6.0 30.8 4.6
After 6 months, T6 161 58.6 7.9 368.6 57.1 38.9 5.6 30.9 4.3
T1-T0 179 0.26 1.34 -1.92 25.7 0.22 5.1 0.19 1.49
P(t) 0.01 ns ns ns
T3-T0 171 0.42 1.76 -4.89 30.7 -0.51 5.5 0.49 2.40
P(t) 0.002 0.04 ns 0.008
T6-T0 161 0.64 1.94 -6.11 31.2 -1.11 6.5 0.51 2.07
P(t) <0.001 0.01 0.03 0.002
T0, T1, T3, T6 = screening visit, after 1 month, 3 months, and 6 months
T1-T0, T3-T0, T6-T0 = change in parameters after 1 month, 3 months, and 6 months
t = Student's t test for paired dataPage 4 of 9
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shown by the 95% confidence ellipse of mean differences
that didn't overlap zero (Figure 1) (P < 0.05, (Hotelling's
T2 test for paired data). In agreement with the basic pat-
tern of vector analysis, the decrease in both vector compo-
nents indicates an increase in soft tissue hydration [2-
4,16].
We evaluated the distribution of body weight, impedance
vector, and TBW by previous contraception method in
173 subjects forming the groups "no method", "oral con-
traceptives" and "barrier methods" (Table 2). At T0, body
weight and impedance vector did not differ among the
three previous contraception methods. At baseline, there
was a significant difference in TBW among the three meth-
ods, due to a greater estimate in the group previously
using barrier methods (31.7 L) compared to the group
using no method (29.8 L). This result is in contrast with
the similar impedance measurements obtained in the
three groups at T0 (Figure 2). Also after 1 month with
transdermal patch, TBW differed among groups due to the
same inequality (32 L in barrier vs 30.1 L in none). How-
ever, after 1 month there was neither significant difference
in changes in body weight, impedance vector, nor TBW
among previous contraception methods (Table 2).
Indeed, as shown in Figure 3, the three 95% confidence
ellipses of impedance vector displacements after 1 month
were overlapping, suggesting no difference in body com-
position changes among groups.
Arterial blood pressure did not significantly change over
time. Systolic blood pressure was 113 mmHg (SD 10) at
T0 and 114 mmHg at T6 (SD 10); diastolic blood pressure
was 71 mmHg at T0 (SD 7) and 71 mmHg at T6 (SD 7).
Discussion
In this study we tested whether a 6-month treatment with
the ethinylestradiol/norelgestromin contraceptive patch
induced changes in body composition, particularly in
body fluid volume. After a treatment of 6 months we doc-
umented a small but statistically significant increase in
body weight, 0.64 kg (1.1%), that has been due to an
increase in soft tissue hydration of similar amount (TBW
0.51 L, 1.7%). This quantity of fluid is within the physio-
logical range of interstitial gel’s hydration fluctuations
[18,19]. In fact, we interpreted this small increase in soft
tissue hydration as a physiological change in the intersti-
tial gel fluid which may represent an adaptation to the
estrogen component of the patch. As gel fluids are not free
to move inside vessels, it does not increase the blood vol-
ume [18,19]. Consistently, we did not document any
effect on blood pressure.
Therefore, the changes in body weight occurred in our
study are clinically not relevant. None of our women
dropped out for weight gain, fluid retention or percep-
tions of them. In this study, women's acceptability and
satisfaction with the contraceptive patch were high, their
compliance remarkably good and, after 6 months, the
majority of subjects indicated that they would continue
using the patch.
According to Guyton's theory [18], fluid overload is
detectable as apparent edema when interstitial pressure
becomes positive due to an increase of interstitial fluid
volume above 30% (meaning increase > 4–5 kg body
weight, or > 12% TBW). In a normal subject (40 liters of
TBW), the interstitial fluid volume is 15 liters in a gel form
and with a negative interstitial pressure of – 2 mmHg, the
blood volume is 5 liters, and tissue impedance is normal.
When the interstitial fluid pressure rises above zero most
of the extra fluid is free fluid allowing the appearance of
pitting edema and shortening the impedance vector due
to a decrease of both vector components. Hence, vector
migration on the R-Xc plane can be used in monitoring
Impedance vector displacements after 1 month, 3 months and 6 months with their 95% confid nce ellipsesFigure 1
Impedance vector displacements after 1 month, 3 
months and 6 months with their 95% confidence 
ellipses. Impedance vector displacements (arrows) after 1 
month (T1-T0), 3 months (T3-T0) and after 6 months (T6-
T0) with their 95% confidence ellipses. The vector displace-
ment after 6 months is significantly different from zero (P < 
0.05, 95% confidence ellipse not overlapping zero), due to a 
decrease in both components R/H and Xc/H. R is resistance, 
Xc reactance, H height, and d difference with respect to the 
screening visit T0.Page 5 of 9
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fluid overload [16,19].
Also a recent review on transdermal hormonal contracep-
tion concludes that patch users generally experience min-
imal, clinically not relevant, changes in body weight [14].
In a recently published meta-analysis on 47 articles [13]
there was no evidence supporting a causal association
between combined oral contraceptive or a combined skin
patch and weight gain. Interestingly, in 15 studies that
used ethinylestradiol 20 μg in one arm of treatment, 4
considered weight change at 3, 4, or 6 months and found
a range from -0.11 to 0.88 kg (compared to our 0.64 kg)
[20-23]. Three studies considered mean body mass per-
centage change (1.1% as in our population). Other stud-
ies evaluated the odds ratio of a relevant weight gain, that
was set to > 2 kg of weight or >5%. Analyzing the daily
weights of 128 women in treatment with oral contracep-
tives, Rosenberg found that there were minor fluctuations,
clinically not relevant, of body weight during each cycles,
confirming that weight gain is a myth or a misperception
[24].
We used BIA methods to establish the nature of the body
weight change. Clinical validation studies established that
a change in the body weight due to a fat mass change in
the order of 10 kg does not displace the impedance vector.
In contrast, a change in the body weight due to a fluid vol-
ume change in the order of 0.5 L is detected as a vector dis-
placement parallel to the major axis of vector's tolerance
and confidence ellipses (i.e. change in both R/H and Xc/
H components) [2,16,25]. Conventional BIA equations
are functions not only of R but also of the body weight.
Any body weight change will yield a change in TBW and
in both fat and fat-free mass due to the assumption of
fixed hydration of soft tissues [25]. With Vector BIA we
documented the same pattern of increased hydration of
soft tissues as found by Lukaski in pregnancy in a larger
scale of hydration [4]. With conventional BIA we esti-
mated an increase in TBW that was in the expected range
for normal tissue hydration (TBW = 73% of 0.64 kg soft
tissue, i.e. 0.47 L). After 1 month with transdermal patch
there was no significant difference in changes in body
weight, impedance vector, nor TBW among previous con-
traception methods (Table 2).
Although we are more confident in Vector BIA as a tool for
body composition in any clinical condition [16,19], we
estimated TBW for the sake of comparison with the scanty
literature, where impedance values are not reported but
comparable TBW values were found [26,27]. We found
conflicting indications from TBW vs Vector BIA, probably
due to the high standard error of BIA prediction equation
estimates [4,15]. For instance after 3 months, the esti-
mated TBW increase (0.49 L) was greater than the body
weight increase (0.42 kg); at T0 there was a significant dif-
ference in TBW among the three previous contraception
methods, although body weight and impedance vector
did not differ among the three methods (Fig. 2). This may
occur because the prediction error of BIA equations is the
sum of five errors, namely the impedance measurement
error, the regression error against the reference method,
the intrinsic error of the reference method, the electric-
volume model error, and the biological variability among
subjects. Vector BIA only needs to take care of the measure-
ment error and of the biological variability of subjects.
Table 2: Distribution of body composition parameters by previous contraceptive method
Body weight, kg R/H, Ohm/m Xc/H, Ohm/m TBW, L
Visit n M SD M SD M SD M SD
T0/CM = 1 92 57.3 8.1 380.9 52.5 40.2 6.7 29.8 3.5
T0/CM = 2 40 59.4 8.4 373.0 45.7 39.0 7.1 30.8 3.4
T0/CM = 3 41 59.2 8.1 356.8 62.8 39.8 5.9 31.7 4.1
P(ANOVA) ns ns ns 0.02
T1/CM = 1 89 57.8 8.2 376.4 51.5 40.6 5.7 30.1 3.8
T1/CM = 2 40 59.2 8.4 373.4 47.0 39.5 6.4 30.8 3.5
T1/CM = 3 41 59.4 8.0 354.8 67.5 39.5 5.4 32.0 4.6
P(ANOVA) ns ns ns 0.04
T1-T0/CM = 1 89 0.40 1.42 -2.48 26.6 0.50 5.4 0.21 1.58
T1-T0/CM = 2 40 -0.18 1.12 0.42 31.6 0.43 5.2 -0.02 1.56
T1-T0/CM = 3 41 0.28 1.19 -2.06 19.5 -0.27 4.4 0.29 1.37
P(ANOVA) ns ns ns ns
CM = previous contraceptive method: 1 none, 2 oral contraceptive, 3 barrier method
ANOVA = Analysis of variance
T0, T1 = screening visit, after 1 month
T1-T0 = change in parameters after 1 monthPage 6 of 9
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hydration independent of the body weight change
[16,19].
However, estimates of TBW and of derived compartments
(fat and fat-free mass) with BIA prediction equations are
not useful in the individual subject due to the high predic-
tion error [4,5,15]. Even weaker is the validity of the esti-
mation of intra- and extracellular fluid with
multifrequency BIA [16,28,29] due to tissue anisotropy
(part of the current flow is intracellular at low frequen-
cies). For these reasons we used the standard, 50 kHz fre-
quency current (which has the best signal-to-noise ratio)
and the Vector BIA which is very sensitive to biological
variation of measurements without the need of regression
equations [4,16].
The sensitivity of Vector BIA in detecting changes in soft
tissue hydration of less than 1 L (0.64 kg of body weight)
could help clinicians in routine, objective monitoring of
the patients’ body fluid volume, particularly with patients
who have the perception of increased body fluid volume
of patients, particularly of those with the perception of
increased body fluid volume.
Our findings were documented in a "real world" popula-
tion by using broad criteria for age (18 to 45 yr) and BMI
(16 to 31 kg/m2). Validity of results can therefore be
extended to the routine clinical setting, while this is not
possible for other studies on extremely selected subjects
(e.g. age 18 to 38 yr, and BMI 21 to 25 kg/m2) [30].
Finally, even if our women had been monitored only for
6 months, we are quite confident that we would have
obtained more or less the same results with a longer study
period. As for body weight, in other published studies the
patch was used for up to 13 cycles showing no significant
signs of weight gain. As for body composition, other pub-
lished trials evaluating the effect of oral contraceptives on
Mean impedance vectors with their 95% confidence ellipses at the scr eni g visit, by previous contra eption m thodFigure 2
Mean impedance vectors with their 95% confidence 
ellipses at the screening visit, by previous contracep-
tion method. Mean impedance vectors with their 95% con-
fidence ellipses at the screening visit. Labels to the vectors 
represent three groups according to the previous contracep-
tion method, vector a from 92 subjects following no method, 
vector b from 40 subjects taking oral contraceptives, and 
vector c from 41 subjects using barrier methods. Overlap-
ping confidence ellipses indicate a comparable distribution of 
vectors among groups.
Impedance vector displacements after 1 month, by previous contraception methodFigure 3
Impedance vector displacements after 1 month, by 
previous contraception method. Impedance vector dis-
placements (arrows) after 1 month. Labels to the vectors 
represent three groups according to the previous contracep-
tion method (as in Figure 2). Overlapping confidence ellipses 
indicate a comparable change of vectors in the three groups.Page 7 of 9
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months [14,26,27,30,31].
An important limitation of the study is the lack of a con-
trol group. However, a randomised controlled trial com-
paring a combined contraceptive method with a placebo
or non-hormonal method for contraception raises ethical
issues. As a rough surrogate we classified subjects accord-
ing to their contraception method used in the three
months before study entry (no method versus oral contra-
ceptives versus barrier method) and we compared changes
in body composition at entry and after 1 month of treat-
ment. With Vector BIA we proved that there was neither a
baseline difference nor a differential change in body com-
position associated with contraception methods used in
the three months before.
In any case, present findings will prompt a comparative,
or, if ethically acceptable, a placebo/non-hormonal con-
trolled trial with a longer follow up period.
Conclusion
After 6 months with the ethinylestradiol/norelgestromin
contraceptive patch we did not find clinically relevant
changes either in body weight or composition, reinforcing
observation from other published studies. The minimal
increase in body weight, less than 1 kg, could be attributed
to an adaptive interstitial gel hydration, physiological as
confirmed by the lack of any effect on blood pressure. This
could be useful in increasing women's choice, acceptabil-
ity and compliance of the ethinylestradiol/nore-
lgestromin contraceptive patch. However, further studies,
including comparative or controlled trials with a longer
follow up period, will help have more robust data con-
cerning the effect of hormonal contraception on body
composition.
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